Your browser is no longer supported. Please, upgrade your browser.
ACIU AC Immune SA daily Stock Chart
AC Immune SA
Index- P/E10.77 EPS (ttm)0.70 Insider Own47.90% Shs Outstand72.53M Perf Week18.27%
Market Cap544.70M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float41.74M Perf Month2.46%
Income46.70M PEG- EPS next Q-0.15 Inst Own26.70% Short Float0.93% Perf Quarter-13.48%
Sales114.00M P/S4.78 EPS this Y177.60% Inst Trans0.05% Short Ratio2.29 Perf Half Y51.72%
Book/sh3.89 P/B1.93 EPS next Y4.50% ROA14.90% Target Price12.10 Perf Year55.17%
Cash/sh4.09 P/C1.84 EPS next 5Y- ROE16.80% 52W Range4.07 - 10.14 Perf YTD-11.85%
Dividend- P/FCF9.94 EPS past 5Y26.30% ROI16.20% 52W High-25.94% Beta0.45
Dividend %- Quick Ratio16.70 Sales past 5Y29.70% Gross Margin- 52W Low84.52% ATR0.70
Employees115 Current Ratio16.70 Sales Q/Q-21.40% Oper. Margin40.10% RSI (14)58.44 Volatility11.92% 13.16%
OptionableYes Debt/Eq0.01 EPS Q/Q-24.70% Profit Margin40.90% Rel Volume0.76 Prev Close7.58
ShortableYes LT Debt/Eq0.01 EarningsApr 09 BMO Payout0.00% Avg Volume169.31K Price7.51
Recom1.70 SMA2029.56% SMA502.08% SMA20014.43% Volume128,907 Change-0.92%
Feb-01-19Downgrade UBS Buy → Neutral
Jan-04-19Initiated UBS Buy
Apr-05-18Initiated H.C. Wainwright Buy $18
Mar-23-18Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Outperform
Oct-18-16Initiated Jefferies Buy $25
Oct-18-16Initiated Credit Suisse Outperform $18
Apr-04-20 08:04AM  Newsflash: AC Immune SA (NASDAQ:ACIU) Analysts Have Been Trimming Their Revenue Forecasts Simply Wall St.
Apr-02-20 07:00AM  AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases GlobeNewswire +6.01%
Mar-30-20 07:00AM  AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook GlobeNewswire +14.96%
Mar-24-20 10:31AM  Company News for Mar 24, 2020 Zacks +7.81%
Mar-23-20 07:00AM  AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer Tau Partnership GlobeNewswire +13.50%
Mar-20-20 07:19AM  Internationally Renowned Neurologist Dr. Juan Fortea Joins AC Immunes Clinical Advisory Board GlobeNewswire
Mar-18-20 09:43AM  Moderna (MRNA) Catches Eye: Stock Jumps 6.4% Zacks -10.55%
Mar-13-20 09:22AM  Guardant Health (GH) in Focus: Stock Moves 6.5% Higher Zacks -5.27%
Mar-05-20 07:00AM  AC Immune to Present New Data Demonstrating the Depth of its Neurodegenerative Programs at the Upcoming Advances in Alzheimers and Parkinsons Therapies Focus Meeting GlobeNewswire
Feb-24-20 07:23AM  Is AC Immune SA's (NASDAQ:ACIU) CEO Pay Justified? Simply Wall St. -6.42%
Jan-30-20 10:37AM  Top Ranked Momentum Stocks to Buy for January 30th Zacks
Dec-24-19 04:57AM  AC Immune SA (NASDAQ:ACIU) Has A ROE Of 17% Simply Wall St.
Dec-16-19 01:46PM  Did Hedge Funds Drop The Ball On AC Immune SA (ACIU) ? Insider Monkey
Nov-14-19 07:00AM  AC Immune to Present at Jefferies 2019 London Healthcare Conference GlobeNewswire +5.21%
Nov-13-19 07:00AM  AC Immune Q3 2019 Financial Results and Business Update GlobeNewswire +16.61%
Nov-11-19 07:50AM  5 Biotech Stocks Set to Beat Q3 Earnings Estimates Zacks
Nov-08-19 10:25AM  Linde (LIN) to Report Q3 Earnings: What's in the Cards? Zacks
Nov-06-19 04:05PM  AC Immune Hosts Key Opinion Leader Event: Untangling Tau Pathology to Treat Alzheimers and Neurodegenerative Diseases GlobeNewswire
02:31PM  Were Hedge Funds Right About Souring On AC Immune SA (ACIU)? Insider Monkey
Nov-05-19 10:33AM  AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-24-19 07:00AM  AC Immune to Host Key Opinion Leader Event: Untangling Tau Pathology to Treat Alzheimers and Neurodegenerative Diseases GlobeNewswire
Sep-25-19 08:52AM  These Factors Make AC Immune SA (NASDAQ:ACIU) An Interesting Investment Simply Wall St.
Sep-23-19 01:22PM  AC Immune to Earn Milestone From Lilly for Alzheimer's Drug Zacks
Sep-20-19 10:02AM  6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day Zacks
07:00AM  AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer Program GlobeNewswire
Sep-17-19 02:00AM  AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620 GlobeNewswire
Sep-04-19 07:00AM  AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinsons Disease Diagnostic Imaging Agent GlobeNewswire
Aug-19-19 12:31PM  Is AC Immune (NASDAQ:ACIU) Using Too Much Debt? Simply Wall St. +6.51%
Aug-14-19 07:00AM  AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update GlobeNewswire
Aug-12-19 07:00AM  AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases GlobeNewswire
Aug-07-19 10:30AM  Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-18-19 10:26AM  AC Immune Initiates Phase I Study for Alzheimer's Disease Zacks -6.96%
Jul-17-19 07:00AM  AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer, an Investigational Treatment for Alzheimers Disease GlobeNewswire +5.56%
Jul-11-19 08:00AM  AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimers Disease-like Symptoms in Subjects with Down Syndrome GlobeNewswire
Jul-10-19 10:52AM  Introducing AC Immune (NASDAQ:ACIU), The Stock That Slid 66% In The Last Year Simply Wall St.
Jun-29-19 06:07PM  Heres What Hedge Funds Think About AC Immune SA (ACIU) Insider Monkey
Jun-28-19 08:36AM  AC Immune Announces Election of New Chairman of the Board at Annual General Meeting GlobeNewswire
Jun-27-19 07:00AM  AC Immune to Host Key Opinion Leader Meeting on Treating Alzheimers in Down Syndrome GlobeNewswire
Jun-20-19 07:00AM  AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimers Disease GlobeNewswire
May-15-19 08:35AM  AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates Zacks
07:36AM  AC Immune: 1Q Earnings Snapshot Associated Press
07:00AM  AC Immune Reports Q1 2019 Financial Results and Business Update GlobeNewswire
May-08-19 01:27PM  Heres What Hedge Funds Think About AC Immune SA (ACIU) Insider Monkey
Apr-24-19 10:33AM  AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth Zacks
Apr-09-19 07:02AM  What Percentage Of AC Immune SA (NASDAQ:ACIU) Shares Do Insiders Own? Simply Wall St.
Apr-03-19 09:58AM  Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003 Zacks
Apr-01-19 07:00AM  AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-29-19 02:00AM  AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD Conference GlobeNewswire
Mar-27-19 10:48AM  Lilly (LLY) Signs New Immunology Deal With Private Biotech Zacks
07:00AM  New Clinical Data on AC Immunes Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD Conference GlobeNewswire
Mar-26-19 09:00AM  What Makes AC Immune (ACIU) a New Buy Stock Zacks
Mar-21-19 07:00AM  AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-04-19 09:59AM  AC Immune to Report Progress of Early-Stage Pipeline at AD/PD Congress GlobeNewswire
Feb-21-19 08:55AM  Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings? Zacks +9.98%
Feb-20-19 08:54AM  Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings? Zacks
07:35AM  What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings? Zacks
07:00AM  AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimers Disease GlobeNewswire
Feb-07-19 07:00AM  AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development GlobeNewswire
Feb-06-19 09:10AM  What Makes AC Immune (ACIU) a New Buy Stock Zacks
Feb-01-19 08:37AM  AC Immune Enters Oversold Territory Zacks
Jan-30-19 04:47PM  Roche Halts Two Late-Stage Studies on Alzheimer's Candidate Zacks -65.98%
04:42PM  Roche Scraps Alzheimer's Test But Investors Punished This Stock Investor's Business Daily
11:41AM  Roche, AC Immune drop Alzheimer drug trials after setback Reuters
10:16AM  Why AC Immune SA Is Imploding Motley Fool
09:49AM  Genentech kills big drug study in early Alzheimer's patients American City Business Journals
01:36AM  Roche drops Alzheimer drug trials after setback Reuters
01:00AM  AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimers Disease GlobeNewswire
Jan-25-19 10:30AM  Top Ranked Momentum Stocks to Buy for January 25th Zacks +5.44%
Jan-23-19 10:01AM  Top Ranked Momentum Stocks to Buy for January 23rd Zacks -5.36%
Jan-22-19 06:42AM  Top Ranked Momentum Stocks to Buy for January 22nd Zacks
Jan-17-19 06:56AM  Moving Average Crossover Alert: AC Immune Zacks
Jan-16-19 09:01AM  Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher Zacks
Jan-07-19 03:51PM  Biogen Inks Two Deals to Make Drugs for Neurological Diseases Zacks
Jan-03-19 04:00AM  AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer GlobeNewswire -7.73%
Dec-19-18 07:16AM  WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership PR Newswire -7.92%
06:31AM  AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership GlobeNewswire
Dec-13-18 09:00AM  Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug Zacks +5.41%
Dec-12-18 07:51AM  Lilly partners with AC Immune for Alzheimer's treatment Reuters
06:51AM  Lilly partners with AC Immune for Alzheimer's treatment Reuters
06:31AM  AC Immune and Lilly Announce License and Collaboration Agreement GlobeNewswire
06:10AM  Lilly partners with AC Immune for Alzheimer's treatment Reuters
06:00AM  Lilly and AC Immune Announce License and Collaboration Agreement PR Newswire
Dec-07-18 04:16PM  In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away GlobeNewswire
Dec-06-18 09:42AM  What You Must Know About AC Immune SAs (NASDAQ:ACIU) Beta Value Simply Wall St.
Nov-30-18 05:37AM  AC Immune (ACIU) Shares March Higher, Can It Continue? Zacks
Nov-15-18 04:01AM  AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease GlobeNewswire +9.16%
Nov-13-18 07:30AM  AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01AM  AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Nov-12-18 04:01AM  AC Immune to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-09-18 04:01AM  AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases GlobeNewswire
Nov-05-18 10:30AM  Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline Zacks
Nov-01-18 06:01AM  AC Immune to Present at 2018 Society for Neurosciences Meeting GlobeNewswire +5.31%
05:01AM  AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases GlobeNewswire
Oct-29-18 06:01AM  AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620 GlobeNewswire -5.74%
05:00AM  AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy GlobeNewswire
Oct-25-18 04:00AM  AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona GlobeNewswire -7.79%
Oct-22-18 04:01AM  AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence GlobeNewswire -5.50%
Oct-17-18 08:35AM  Investor Expectations to Drive Momentum within Matthews International, AC Immune SA, Entercom Communications, Sunrun, Axcelis Technologies, and Advanced Disposal Services Discovering Underlying Factors of Influence GlobeNewswire
Aug-22-18 08:15AM  Recent Analysis Shows STMicroelectronics N.V, Jagged Peak Energy, Inovalon, AC Immune SA, Repligen, and RealNetworks Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-20-18 04:01AM  AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome GlobeNewswire
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.